碘化钾与伊曲康唑联合治疗孢子丝菌病的实验研究

目的观察碘化钾与伊曲康唑单独用药和联合用药对实验性孢子丝菌感染的治疗作用。方法建立小鼠孢子丝菌皮内和系统感染模型,分别设立对照组、碘化钾组、伊曲康唑组及碘化钾和伊曲康唑联合用药组,检测各组真菌培养阳性率、组织中孢子数目及炎症浸润细胞的变化。结果与对照组比较,用药组皮内感染皮损中孢子数目减少,系统感染组织器官真菌培养阳性率降低,联合用药组与单独用药组上述两指标比较均有显著性差异。皮内感染三个用药组都可引起炎症细胞的浸润增加,联合用药组以巨噬细胞的增加尤为明显。结论碘化钾与伊曲康唑联合治疗小鼠孢子丝菌皮内感染和系统感染均优于两种药物单独应用。     

伊曲康唑治疗孢子丝菌病的疗效及抗真菌药敏试验

目的:观察伊曲康唑对孢子丝菌病的临床疗效,检测孢子丝菌对伊曲康唑的体外敏感性.方法:对48例孢子丝菌病患者给予伊曲康唑胶囊口服治疗;另外30例患者给予碘化钾溶液口服治疗,并采用Etest法检测其中10株孢子丝菌对伊曲康唑的最小抑菌浓度(MIC).结果:伊曲康唑对孢子丝菌病的总有效率91.67％,碘化钾溶液的总有效率86.67％,两组总有效率比较无显著性差异,(P＞0.05).采用Etest法检测10株孢子丝菌对伊曲康唑MIC值,范围为0.012-8μg/mL.结论:虽然伊曲康唑对孢子丝菌病的疗效与碘化钾的疗效相当,但副作用小.Etest法可以作为一种孢子丝菌的体外抗真菌药敏试验方法.     

伊曲康唑治疗糠秕孢子菌毛囊炎疗效观察

采用伊曲康唑治疗糠秕孢子菌毛囊炎30例,患者每日服用伊曲康唑200mg,连服7天,并与2%酮康唑洗剂对照。结果伊曲康唑组总有效率97%,对照组总有效率为73%,两组疗效相比有显著性差异。     

不同抗真菌药物对艾滋病合并马尔尼菲篮状菌病临床疗效及体外药敏试验结果分析

目的观察艾滋病合并马尔尼菲篮状菌病患者体外真菌药敏结果和不同抗真菌治疗方案的疗效。方法将酵母相马尔尼菲篮状菌调成菌悬液并转移至药敏培养基中混匀,然后将混匀的酵母菌悬浮液接种到ATBTMFUNGUS 3酵母样真菌敏感性检测试纸条上孵育,可以通过肉眼判读杯状凹中酵母菌的生长情况,获得两性霉素B、伊曲康唑、伏立康唑、氟康唑、氟胞嘧啶的最小抑菌浓度(minimum inhibitory concentration,MIC);同时临床观察不同抗真菌药物治疗的疗效。结果84株马尔尼菲篮状菌均显示两性霉素B MIC<0.5 mg/L,伊曲康唑MIC<0.125 mg/L,伏立康唑MIC<0.06 mg/L。73株(86.90%)马尔尼菲篮状菌显示氟康唑MIC≥1 mg/L。69株(82.14%)马尔尼菲篮状菌显示氟胞嘧啶MIC≥4 mg/L。药敏结果显示马尔尼菲篮状菌对两性霉素B、伊曲康唑和伏立康唑的MIC均处于低水平,而对氟康唑和氟胞嘧啶MIC均处于高水平。84例患者中有7例未接受抗真菌治疗者均死亡,77例患者接受了抗真菌治疗,其中74例治疗好转,治疗好转率96.10%。两性霉素B治疗组好转率96.88%,伏立康唑治疗组好转率92.31%,两组比较差异无统计学意义(P=0.43)。结论艾滋病合并马尔尼菲篮状菌病可以选择两性霉素B、伏立康唑和伊曲康唑治疗,不推荐选择氟康唑和氟胞嘧啶治疗。     

伊曲康唑治疗不同免疫状态下小鼠白念珠菌性阴道炎的实验研究

目的：研究不同免疫状态下伊曲康唑治疗小鼠白念珠菌性阴道炎的疗效。方法：构建ICR小鼠白念珠菌性阴道炎模型，并应用地塞米松构建免疫抑制鼠模型；采用伊曲康唑灌服治疗；其中F组同时采用γ-IFN治疗，在灌药后不同时间动态观察阴道灌洗液真菌载量。结果：伊曲康唑治疗正常免疫组（A组）与对照组（D组）之间的疗效差异有显著性（P〈0．01）；免疫抑制组（E组）及免疫抑制后并进行免疫调节治疗组（F组）与对照组（G组）之间差异均有显著性（P〈0．01）；而A、E、F组在接种后的第5、6、7、9、11天其阴道灌洗液真菌载量无明显差异（P〉0．05）。结论：伊曲康唑治疗不同免疫状况（即正常免疫、免疫抑制、免疫调节治疗状态下）的小鼠白念珠菌性阴道炎疗效均显著，而且正常免疫、免疫抑制及免疫增强状态下对伊曲康唑的抗真菌疗效无明显影响。     

光动力疗法单用或联合抗真菌药物对游离态及形成生物膜的皮炎外瓶霉凋亡的影响

目的 探讨光动力疗法单用或联合抗真菌药物对游离态及形成生物膜的皮炎外瓶霉凋亡的作用。方法 制备皮炎外瓶霉游离态孢子悬液,用改良的96孔板法构建皮炎外瓶霉生物膜。将皮炎外瓶霉游离态孢子和生物膜分别分为单药组（只用抗真菌药物处理）、光动力组（只用光动力处理）和光动力联合药物组（先用光动力处理,再用抗真菌药物处理）,同时设立空白对照组（既不用抗真菌药物处理也不用光动力处理）,抗真菌药物包括两性霉素B、泊沙康唑、伏立康唑和伊曲康唑,药物浓度均为1 mg/L,处理时间均为2 h。采用末端脱氧核苷酸转移酶介导的dUTP 缺口末端标记（TUNEL）法进行凋亡检测。结果 抗真菌药及光动力疗法对游离态（均P < 0.001）及形成生物膜（均P < 0.05）的皮炎外瓶霉凋亡率均有影响。空白对照组和两性霉素B、泊沙康唑、伏立康唑、伊曲康唑单药组游离态皮炎外瓶霉凋亡率分别为11.67% ± 0.21%、13.30% ± 1.78%、14.30% ± 3.61%、14.51% ± 1.91%、36.17% ± 4.00%,其中伊曲康唑单药组凋亡率显著高于空白对照组（P < 0.05）,其他3个单药组与空白对照组差异均无统计学意义（均P > 0.05）。光动力组游离态孢子凋亡率（41.37% ± 7.80%）显著高于空白对照组（P < 0.05）。光动力联合两性霉素B、泊沙康唑、伏立康唑、伊曲康唑组的游离态孢子凋亡率分别为29.23% ± 6.71%、37.23% ± 10.86%、43.57% ± 6.42%、69.87% ± 3.53%）,其中联合伏立康唑、伊曲康唑组凋亡率显著高于相应单药组（均P < 0.05）。光动力组生物膜凋亡率（32.00% ± 0.43%）显著高于空白对照组（25.30% ± 1.31%,P < 0.05）,光动力联合两性霉素B组显著高于两性霉素B组（P < 0.05）。结论 光动力联合抗真菌药物能够明显促进游离态及形成生物膜的皮炎外瓶霉的凋亡。     

真菌病

20091816 两种培养基在ROSCO真菌药敏试验中的应用/胡丽华(浙江省皮防所检验科),陶亦帆∥中国皮肤性病学杂志.-2009,23(4).-247～248将141株念珠菌用改良Shadomy琼脂和亚甲蓝M-H琼脂和4种丹麦Rosco抗真菌药敏片,分别进行培养及药敏试验。结果两种培养基对两性霉素B、氟胞嘧啶、氟康唑和伊曲康唑敏感试验的符合率分别为100%,46.81%,83.69%和92.20%,敏感性分别为100%,53.19%,80.85%和94.33%,两种培养基对氟康唑和氟胞嘧啶药敏结果差异有统计学意义而对两性霉素B和伊曲康唑则无统计学意义。认为两种培养基在两性霉素和伊曲康唑敏试验     

性病门诊生殖器念珠菌病的易感因素、致病菌和药敏检测分析

目的了解性病门诊生殖器念珠菌病的易感因素、致病菌及对抗真菌药物的敏感性。方法收集疑似病例,通过真菌学确诊后进行流行病学调查,并进行菌种鉴定和体外药敏试验。结果168例疑似患者共分离培养出念珠菌46株(白念珠菌44株占95.6%、克柔念珠菌1株、光滑念珠菌1株);配偶/性伴患病、广谱抗菌素的应用等与本病相关;对抗真菌药的敏感性分别为酮康唑(KCZ)97.7%、伊曲康唑(ICZ)84.1%、特比萘芬(TBF)63.6%、两性霉素B(AMB)88.6%、咪康唑(MCZ)93.2%、氟康唑(FCZ)95.5%、5-氟胞嘧啶(5-FC)90.9%;ICZ和KCZ对FCZ耐药株的最低抑菌浓度(MIC)值偏高。结论配偶/性伴患病是最主要的易感因素;致病菌以白念珠菌为主,唑类药物存在交叉耐药倾向。     

国内首见真皮毛孢子菌引起皮肤感染一例

目的 报道1例真皮毛孢子菌引起的皮肤感染。方法 取皮损作直接镜检、真菌培养和组织病理学检查,分离菌株行DNA序列分析、API 20C AUX试剂盒检测、明胶液化试验、温度试验和体外药敏试验。结果 70岁男性患者,右内踝植物刺伤后出现肿块、溃疡9个月。皮损直接镜检阴性,组织病理显示真皮内菌丝和孢子。沙氏葡萄糖琼脂培养基培养出奶黄色酵母样菌落,微量培养可见假菌丝、真菌丝、关节孢子和芽生孢子,API 20C AUX试剂盒检测结果提示为土生念珠菌,DNA序列分析属于真皮毛孢子菌。菌株不能液化明胶,可在25 ～ 40 ℃环境下生长,对两性霉素B、伊曲康唑、伏立康唑、制霉菌素敏感。伊曲康唑治疗4个月后皮损完全愈合。结论 根据其形态学特点和DNA序列分析,菌株被鉴定为真皮毛孢子菌。伊曲康唑治疗有效。     

伊曲康唑冲击治疗皮肤播散性红色毛癣菌病1例

伊曲康唑400mg/天，连续一周冲击治疗，辅以增强免疫功能及对症治疗，治愈皮肤播散性红色毛癣菌病一例。皮损和组织真菌镜俭和培养均为阴性。随访十月，未复发。     

D-半乳糖诱导大鼠皮肤衰老的形态学与生化指标观察

目的 观察D-半乳糖诱导皮肤衰老大鼠的皮肤形态学改变及与衰老相关的生化指标变化。方法 26只SD雌雄大鼠随机分为2组:D-半乳糖组每天给予D-半乳糖皮下注射120mg·kg^-1·d^-1,对照组皮下注射等量生理盐水。喂养100d后处死大鼠,观察血液和皮肤中与衰老相关的生化指标,并行皮肤组织病理学检查,用计算机图像分析系统定量分析表皮厚度、弹力纤维的面积。结果 D-半乳糖组大鼠表皮变薄,胶原纤维及弹力纤维减少,排列疏松,呈现与人类皮肤衰老相似的表现。D-半乳糖组大鼠皮肤中羟脯氨酸含量降低,丙二醛含量增加,全血谷胱甘肽过氧化物酶和过氧化氢酶活性降低,红细胞中超氧化物歧化酶活性降低。结论 D-半乳糖120mg·kg-·1d^-1皮下注射100d可导致大鼠皮肤衰老样改变。     

参麦注射液对百草枯所致肺损伤的保护作用

目的探讨参麦注射液在百草枯中毒所致肺损伤中的作用。方法120只SD大鼠随机分为百草枯中毒组（APP）,参麦注射液治疗组（SM1,SM2,SM3）。HE染色观察参麦注射液治疗组组织结构变化,采用免疫组织化学法测定各组肺组织中TGF—β1、IL-1β的表达水平。结果百草枯中毒组肺组织充血水肿明显,肺泡破坏严重,治疗组有所减轻;各治疗组与百草枯中毒组之间转化生长因子β-1（TGF—β1）,白细胞介素-1β（IL—1β）水平均较治疗组明显降低,各治疗组随剂量的增加,TGF-β1,IL-1β水平有明显下降,差异有显著性（P〈0．05）。结论参麦注射液在百草枯所致中毒大鼠肺损伤中能使TGF—β1,IL-1β表达水平下调,减轻肺泡炎症和充血程度,减轻百草枯中毒所致肺损伤,延缓和抑制肺纤维化的发生、发展。     

丹参酮治疗雄激素性秃发大鼠模型的研究

目的：研究丹参酮对二氢睾酮（DHT）诱导的雄激素性秃发（AGA）大鼠模型的治疗作用。方法：32只Wistar雄性大鼠随机分为空白对照组、DHT造模组、丹参酮组及非那雄胺组,每组8只;空白对照组大鼠不予处理,余24只大鼠应用皮下注射5 mg/kg·d DHT的方法建立AGA大鼠模型。DHT造模组大鼠不予干预;丹参酮组大鼠予0.24 g/kg·d丹参酮进行灌胃干预,灌胃从造模的第二天开始,连续给药60 d;非那雄胺组大鼠予0.12 mg/kg·d非那雄胺进行灌胃干预,时间与丹参酮组一致。观察大鼠毛发的形态学改变及皮肤组织病理学改变,检测大鼠血清及组织的雌二醇（E2）、睾酮（T）、DHT、酸性成纤维细胞生长因子（αFGF）、胰岛素样生长因子（IGF-1）、肿瘤坏死因子（TNF-α）、转化生长因子β1（TGF-β1）水平。结果：DHT造模组大鼠背部毛发与空白对照组大鼠相比明显稀疏,部分毛发脱落,血清TNF-α、TGF-β1浓度较空白对照组明显升高（P<0.05）;丹参酮组大鼠与DHT造模组大鼠相比,背部毛发分布整齐,毛发较为浓密;丹参酮组大鼠的血清雌二醇浓度较二氢睾酮造模组显著升高（P<0.05）,血清DHT浓度较DHT造模组明显降低（P<0.05）;丹参酮组大鼠组织αFGF的浓度显著高于DHT造模组大鼠（P<0.05）。结论：丹参酮治疗AGA模型大鼠有效,其治疗AGA的机制与调节组织和循环的激素代谢水平及细胞因子作用相关。     

Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor.

BACKGROUND: Pityriasis (tinea) versicolor has a high tendency to recur after being treated successfully. Prophylactic treatment to reduce recurrence is needed. OBJECTIVE: To determine whether recurrence of pityriasis versicolor could be prevented by prophylactic itraconazole treatment. DESIGN: Open treatment followed by a randomized, double-blind, placebo-controlled phase. SETTING: Multinational outpatient centers. PATIENTS: A total of 239 consecutive patients were included; 238 started open treatment. A total of 209 patients started prophylactic treatment: 106 in the itraconazole group and 103 in the placebo group. INTERVENTIONS: Open treatment: itraconazole, 200 mg once daily for 7 days. Prophylactic treatment: itraconazole, 200 mg, or placebo twice daily 1 day per month for 6 consecutive months. MAIN OUTCOME MEASURES: Mycological cure rates at the end of open treatment and at the end of prophylactic treatment. RESULTS: Mycological cure at the end of open treatment was 92% (205/223). At the prophylactic treatment end point (6 months), mycological cure was 88% (90/102) in the itraconazole group and 57% (56/99) in the placebo group (P<.001). In open treatment, 11 patients were not able to be evaluated for efficacy. In prophylactic treatment, 4 patients in the itraconazole group and 4 in the placebo group were not able to be evaluated. Adverse events were reported during open treatment by 26 patients (11%) and during prophylactic treatment by 17 (16%) in the itraconazole group and 14 (14%) in the placebo group. No patients experienced any serious adverse events. CONCLUSIONS: Prophylactic itraconazole treatment is efficacious for pityriasis versicolor after 6 months, as is itraconazole in the treatment of pityriasis versicolor.     

Itraconazole in the treatment of superficial mycoses—a double-blind study vs. placebo

Ninety-four patients with dermatophytosis and 16 patients with pityriasis versicolor were assigned under double-blind conditions to oral itraconazole (100 mg once daily) or placebo. The medication consisted of two capsules, each containing 50 mg of active substance, or placebo and was given for 15 or 30 days in patients with dermatophytosis and for 15 days in patients with pityriasis versicolor. Patients with pityriasis versicolor who had not responded at the end of the double-blind period were treated on an open basis with itraconazole (100 mg once daily) for 15 days. In the treatment of dermatophyte infections for 30 days, both clinical response and mycological cure were significantly superior in the itraconazole group compared with placebo. Oral administration of itraconazole (100 mg once daily) was also highly efficacious in the treatment of pityriasis versicolor. None of the placebo patients was clinically or mycologically cured at the end of the double-blind phase compared to seven out of eight itraconazole patients. All placebo patients who entered the open phase responded to itraconazole treatment. Three itraconazole-treated patients and nine placebo-treated patients reported side-effects.     

几种抗真菌药物对马尔尼菲青霉的体外药敏试验

目的 观察马尔尼菲青霉（PM）广西野生银星竹鼠寄生株与临床人分离株对伏立康唑和几种常用抗真菌药物的敏感性。方法 采用美国临床实验室标准委员会（CLSI）M27-A2和M38-A方案中的微量稀释法,测定伏立康唑、伊曲康唑、特比萘芬、两性霉素B 及氟康唑对14株广西野生银星竹鼠PM寄生株与25株临床人PM分离株25 ℃菌丝相及37 ℃酵母相的最小抑菌浓度（MIC）。用两样本均数比较t检验比较PM寄生株与临床人PM分离株MIC的差异性,用配对t检验比较同一株菌在两种不同温度相下的MIC差异性。结果 伏立康唑、伊曲康唑、特比萘芬、两性霉素B、氟康唑对PM寄生株菌丝相的MIC分别为：0.0313 ～ 0.1250、0.1250 ～ 1.0000、0.0313 ～ 0.5000、0.2500 ～ 4.0000、2.0000 ～ 8.0000 mg/L;对PM寄生株酵母相的MIC分别为：0.0078 ～ 0.2500、0.0313 ～ 0.5000、0.0313 ～ 1.0000、0.2500 ～ 2.0000、1.0000 ～ 8.0000 mg/L;对PM临床人分离株菌丝相的MIC分别为：0.0313 ～ 0.2500、0.0625 ～ 1.0000、0.0313 ～ 1.0000、0.2500 ～ 4.0000、2.0000 ～ 32.0000 mg/L;对PM临床人分离株酵母相的MIC分别为：0.0039 ～ 0.2500、0.0313 ～ 0.5000、0.0313 ～ 2.0000、0.1250 ～ 2.0000、2.0000 ～ 16.0000 mg/L。5种抗真菌药物对广西野生银星竹鼠PM寄生株与临床人PM分离株菌丝相和酵母相均敏感。同一温度下伏立康唑对两种不同来源PM的MIC最低,其他药物的MIC依次为伊曲康唑、特比萘芬 < 两性霉素B < 氟康唑。同一药物在同一温度下对广西野生银星竹鼠PM寄生株与PM临床分离株的MIC无明显差异;伊曲康唑、两性霉素B、特比萘芬对同一菌株在菌丝相和酵母相下的MIC存在差异。结论 PM对伏立康唑的敏感性最高;来自于广西野生银星竹鼠的PM寄生株与临床人PM分离株对伏立康唑、伊曲康唑、特比萘芬、两性霉素B及氟康唑的MIC类似;菌相的改变可影响PM对伊曲康唑、两性霉素B、特比萘芬的敏感性。     

Itraconazole versus terbinafine (LAMISIL®): which is better for the treatment of onychomycosis?

Objectives To compare the efficacy, safely and tolerability of oral terbinafine with itraconazole in patients with toenail onychomycosis treated for 4 months. Setting Departments of dermatology of six universities and one private clinic. Design Double-blind double-dummy, multicentric, multinational, parallel-group therapeutic trial, involving 179 patients with toenail onychomycosis. Patients were randomly treated with either 200 mg/day oral itraconazole or 250 mg/day terbinafine for 4 months. After the 4th month both treatment groups received oral placebo for another 8 months. The total duration of the study was therefore 12 months. After the 12th month a final evaluation of efficacy was performed in 167 patients (85 on itraconazole and 82 on terbinafine) and a final evaluation of tolerability was performed in 175 patient. Results The dermatophytes identified at the initial visit were Trichophyton rubrum (82.1%), Trichophyton mentagrophytes (14%) and others (3.9%), The mycological cure rates at the end of the 4th and 12th months were 54.9% and 95.3% in the terbinafine group and 51.8% and 84.31% in the itraconazole group (the difference between the groups was. statistically significant at the 12th month, P < 0.04). Clinical cure was achieved by 8.5% and 9.4% of the patients in the terbinafine and itraconazole groups at the 4th month (not significant. NS) and these rates increased to 57.8% and 62.9%. respectively, at the 12th month (difference between groups NS, P > 0,05). A complete mycological cure associated with clinical improvement over 50%. was observed at the 4th month in 50% of the patients treated with terbinafine and 49.4% of the patients treated with itraconazole which was not statistically significant (NS). At the 12th month the rates increased to 95.4% with terbinafine and 75.7% with itraconazole (statistically significant. P < 0.001). Seven patients of the terbinafine group and 9 patients of the itraconazole group presented drug-related side effects (NS). Six patients (6.3%) discontinued the study due to adverse events in the itraconazole group hut no patient discontinued in the terbinafine group. At entry into the study all subjects in both groups presented normal values in liver function tests which remained unchanged throughout the study in the patients of the terbinafine group. One patient of the itraconazole group presented small increases in SGOT and SGPT associated with abdominal pain and nausea.     

Disseminated cutaneous phaeohyphomycosis in immunocompetent child

We present a 6-year-old immunocompetent child with disseminated cutaneous phaeohyphomycosis, affecting his face, arms, thighs, and chest. He was treated with oral itraconazole 100 mg once a day for 5 months and surgical excision of the residual lesions. Disseminated phaeohyphomycosis is very infrequent in immunocompetent children.     

卡泊三醇软膏联合氟芬那酸丁酯软膏治疗神经性皮炎和慢性湿疹疗效观察

目的观察卡泊三醇软膏联合氟芬那酸丁酯软膏治疗神经性皮炎和慢性湿疹的疗效。方法采用随机分组对照试验,试验组白天外用氟芬那酸丁酯软膏,2次/d,晚上外用卡泊三醇软膏,1次/d;对照Ⅰ组白天外用氟芬那酸丁酯软膏,2次/d,晚上外用0.025%维A酸乳膏,1次/d;对照Ⅱ组白天外用0.05%卤米松乳膏,1次/d,晚上外用0.025%维A酸乳膏,1次/d。在治疗前及治疗第4周末评估记录各观察指标,随访6个月观察其复发率。结果用药4周后,有效率试验组(85.00%)与对照Ⅱ组(88.33%)相比,差异无统计学意义(P>0.05),与对照Ⅰ组(70.00%)相比,差异有统计学意义(P<0.05);复发率试验组(19.23%)与对照Ⅰ组(26.09%)相比,差异无统计学意义(P>0.05),与对照Ⅱ组(46.15%)相比,差异有统计学意义(P<0.05)。结论卡泊三醇软膏联合氟芬那酸丁酯软膏治疗神经性皮炎和慢性湿疹疗效显著,复发率低。     

Cutaneous sporotrichosis: a six-year review of 19 cases in a tertiary referral center in Malaysia

Background Sporotrichosis is a subcutaneous fungal infection caused by a thermally dimorphic aerobic fungus, Sporothrix schenckii. It results from traumatic inoculation or contact with animals. Most cases were reported mainly in the tropics and subtropics. Objective The objective of our study is to assess the clinical characteristic of cutaneous sporotrichosis among our patients. Methodology We performed a retrospective review of all cases diagnosed with cutaneous sporotrichosis from July 2004 to June 2010. Patients’ medical records were retrieved and analyzed according to demography, preceding trauma, sites of lesions, clinical subtypes, treatment, and clinical response. Results Nineteen cases were diagnosed with cutaneous sporotrichosis with a male/female ratio of 9 : 10. Thirteen cases (68.4%) were able to recall preceding trauma, and seven of them reported cat scratches or cat bites. Lymphocutaneous sporotrichosis was observed in 13 cases (68.4%) followed by four cases of fixed cutaneous sporotrichosis and two cases of disseminated sporotrichosis. Histologically, 11 cases (57.8%) demonstrated a granulomatous reaction. Sporothrix schenckii was cultured in 12 cases (63.2%). Thirteen cases (68.4%) were successfully treated with oral itraconazole alone for a mean duration of 15.6 weeks. Two cases with disseminated cutaneous sporotrichosis were treated with intravenous amphotericin B. Conclusion Lymphocutaneous sporotrichosis was the most common subtype of cutaneous sporotrichosis in our series, with cat scratches or bites being the most common preceding trauma. Oral itraconazole was highly effective for the localized subtypes, whereas intravenous amphotericin B was required in disseminated cutaneous sporotrichosis.